TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9272365
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccines (aP) from SmithKline Beecham (SB) or Chiron Biocine (CB)
Study: 9272365
Drug: Whole-cell vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell vaccine (wP) from Connaught
Study: 9272365
Drug: Diphtheria and
Normalized name: Diphtheria and tetanus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria and tetanus toxoids (DT) vaccine only
Study: 9163637
Drug: roxithromycin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (4 mg x kg(‐1) b.i.d.) for 12 weeks
Study: 958757
Drug: Brief presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief presentation by a local pharmaceutical representative
Study: 31328540
Drug: Stability and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stability and coordination exercises (20 min) as part of an 80 min cardiac rehabilitation programme, twice a week for 12 weeks
Study: 23725523
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) with dietary supplementation of ascorbic acid (AA) (450 mg) for two weeks
Study: 22050133
Drug: BCAA (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (7 g)
Study: 19931670
Drug: Prostacyclin (20,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin (20,000 ng/mL)
Study: 16263778
Drug: Aggressive treatment/hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment/hospital setting (ATH)
Study: 8422660
Drug: Albendazole 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 7.5 mg/kg twice a day
Study: 8422660
Drug: Albendazole 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 5.0 mg/kg three times a day
Study: 3775071
Drug: 30 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 Gy in 10 daily fractions
Study: 27676362
Drug: Promoting light-intensity
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promoting light-intensity activities of daily living (Control)
Study: 22411639
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl (25 μg)
Study: 17846853
Drug: Ertapenem 1
Normalized name: ertapenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem 1 g/day for 3 days
Study: 17846853
Drug: Ertapenem 1
Normalized name: ertapenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem 1 g/day for >=5 days
Study: 15943731
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose preoperative antibiotics (group A)
Study: 15943731
Drug: Three-dose antibiotics
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose antibiotics (group B)
Study: 15943731
Drug: 5-day perioperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day perioperative antibiotics (group C)
Study: 12182212
Drug: Yohimbine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (8 mg orally twice a day)
Study: 10485636
Drug: Zaleplon, 10
Normalized name: Zaleplon, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon, 10 mg
Study: 10485636
Drug: Zaleplon, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon, 20 mg
Study: 10485636
Drug: Zaleplon, 5
Normalized name: Zaleplon, 5 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon, 5 mg
Study: 10485636
Drug: Zolpidem, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem, 10 mg
Study: 8601845
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (1.3 g x kg‐1 x 24 h‐1)
Study: 8601845
Drug: Trauma patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma patients (no amino acid infusion)
Study: 1899682
Drug: Histamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine infusion starting at 0.2 microgram/kg/min, increased every 5 minutes by 0.1 to 0.2 microgram/kg/min until mean BP fell greater than 15 mm Hg or a dosage of 1.6 micrograms/kg/min was reached.
Study: 30786186
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg daily for up to 180 days)
Study: 30786186
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg daily during intervention period)
Study: 20031857
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy plus percutaneous coronary intervention (PCI)
Study: 15188337
Drug: Lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100 mg/day or less in case of renal insufficiency) and plasma exchanges (3/week for 3 weeks, 2/week for 2 weeks, then 1/week until seroconversion or clinical recovery) after short-term corticosteroids (oral prednisone 1 mg/kg/day for 1 week, then tapered and withdrawn within 1 week).
Study: 9580391
Drug: Protocol 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 1: 200 ml 0.1N citric acid solution 10 min before 75 mg 13C-urea
Study: 9580391
Drug: Protocol 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 2: 200 ml 0.1N citric acid solution simultaneously with 75 mg 13C-urea
Study: 8061726
Drug: Ephedrine 20
Normalized name: DM 10/PSEUDOEPHEDRINE 20MG/5ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 20 mg plus caffeine 200 mg (EC)
Study: 2498931
Drug: Lorazepam (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2.0 mg PO)
Study: 2498931
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (0.3 mg, 1.0 mg, or 3.0 mg IV)
Study: 4629075
Drug: Live adenovirus
Normalized name: Adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live adenovirus type 21 vaccine
Study: 29876777
Drug: Probiotics (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (3.0 × 10^8 CFU/g Streptococcus thermophilus MG510 and 1.0 × 10^8 CFU/g Lactobacillus plantarum LRCC5193) daily for 4 weeks
Study: 24646336
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion discontinued at the onset of active labor (5cm cervical dilatation)
Study: 24646336
Drug: Incremental oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incremental oxytocin infusion maintained until delivery
Study: 24121096
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) plus drug withdrawal
Study: 24121096
Drug: Placebo biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo biofeedback (PL) plus drug withdrawal
Study: 24121096
Drug: Drug withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug withdrawal (MED) only
Study: 15303313
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) 0.625 mg/day plus medroxyprogesterone 2.5 mg/day (n = 6)
Study: 15303313
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day (n = 9)
Study: 9314976
Drug: Phase shift
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase shift contrast agent
Study: 29230803
Drug: Insulin bolus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin bolus
Study: 28339831
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (FCM) targeting higher ferritin (400-600 µg/L)
Study: 28339831
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (FCM) targeting lower ferritin (100-200 µg/L)
Study: 20332194
Drug: 48 h
Normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 h prophylactic antibiotic therapy
Study: 20332194
Drug: 72 h
Normalized name: 72 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72 h prophylactic antibiotic therapy
Study: 6208103
Drug: Remission induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission induction treatment with Ara‐C c. inf. from the first to the eighth day plus Adr. from the first to the third day
Study: 6208103
Drug: Remission induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission induction treatment with Ara‐C + 6‐TG + Adr., 6 + 6 + 2 days
Study: 6208103
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with 5 day course of Ara‐C s.c. in addition to 6‐TG, Vincristine plus Prednisone and Adriamycin
Study: 6208103
Drug: Calf thymus
Normalized name: Calf thymus ribonuclease H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf thymus extract (TFX‐Polfa) in addition to maintenance therapy
Study: 31083077
Drug: AM-111 (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM-111 (0.4 mg/ml)
Study: 31083077
Drug: AM-111 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM-111 (0.8 mg/ml)
Study: 30071702
Drug: Tailored communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored communication regarding patients' oral health based on health literacy levels
Study: 22863642
Drug: High supplement
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High supplement users (≥3 formulations per day)
Study: 18803557
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthesia (EMLA 5% cream)
Study: 18036295
Drug: No anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulation or antiplatelet drugs
Study: 11862356
Drug: Caffeine 600
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 600 mg
Study: 10203414
Drug: Cyclic group
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic group (800 mg twice daily of oral clodronate for 2 weeks every 3 months for the first 12 months)
Study: 10203414
Drug: Continuous group
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous group (400 mg of clodronate once daily for the second 12 months)
Study: 108461
Drug: Nitroglycerin (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.6 to 6.0 mg/h, mean 2.3 mg/h) over 48 hours
Study: 108461
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no specific therapy)
Study: 26914336
Drug: Tzu-Yun Ointment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tzu-Yun Ointment (TYO)
Study: 26914336
Drug: Topical Steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Steroids (TS)
Study: 22095398
Drug: Mericitabine (RG7128)
Normalized name: Emtricitabine
DrugBank: Mericitabine (DB12045)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mericitabine (RG7128) 750 mg administered bid
Study: 22095398
Drug: Mericitabine (RG7128)
Normalized name: Emtricitabine
DrugBank: Mericitabine (DB12045)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mericitabine (RG7128) 1500 mg administered bid
Study: 22095398
Drug: Mericitabine (RG7128)
Normalized name: Emtricitabine
DrugBank: Mericitabine (DB12045)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mericitabine (RG7128) administered qd
Study: 19566665
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg twice weekly re-treatment
Study: 19566665
Drug: Etanercept re-treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept re-treatment
Study: 323316
Drug: Kanamycin gel
DrugBank: Kanamycin (DB01172)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kanamycin gel treatment for one week before and after dental restorations
Study: 24751323
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel treatment
Study: 28605468
Drug: X358 (0.1-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: X358 (0.1-9 mg/kg)
Study: 28605468
Drug: X358 (3-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: X358 (3-9 mg/kg)
Study: 21281461
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (Group CBT) sessions
Study: 9005797
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg twice a day for 3 to 5 days, followed by oral use of the same dosage for 3 to 5 days)
Study: 9005797
Drug: Ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (400 mg once a day for 3 to 5 days)
Study: 9005797
Drug: Ofloxacin (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (same dosage as above for 10 days)
Study: 7047171
Drug: Phenoperidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoperidine (2 mg i.v.)
Study: 7047171
Drug: Diazepam (t
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (t mg i.v.)
Study: 31547291
Drug: Sugar beet
Normalized name: Sugar beet pollen
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar beet pectin (15 g/day)
Study: 25146586
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg, open-label, every 4 weeks for up to 7 years (total of 91 doses)
Study: 22029576
Drug: Physostigmine ointment
Normalized name: physostigmine Ophthalmic Ointment
DrugBank: Physostigmine (DB00981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine ointment after phacoemulsification
Study: 22029576
Drug: Physostigmine ointment
Normalized name: physostigmine Ophthalmic Ointment
DrugBank: Physostigmine (DB00981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine ointment
Study: 19452483
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment with atorvastatin (maximum 80 mg/d)
Study: 19452483
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (continuation of baseline lipid-lowering therapy)
Study: 16721618
Drug: Preoperative intraarticular
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative intraarticular anesthesia (0.1 mg Fentanyl + 8 ml Bupivacain 0.5%)
Study: 16721618
Drug: Postoperative intraarticular
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative intraarticular anesthesia (0.1 mg Fentanyl + 8 ml Bupivacain 0.5%)
Study: 16721618
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block (20 ml Prilocain 1% + 20 ml Bupivacain 0.5%)
Study: 16036026
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockade
Study: 16036026
Drug: Aldosterone receptor
Normalized name: Aldosterone receptor site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone receptor blockade
Study: 7645915
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (enoxaparin) 40 mg once daily, starting 12 hours preoperatively for 10 days
Study: 7645915
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH) 5000 IU twice a day subcutaneously, starting two hours before operation for 10 days
Study: 30325305
Drug: 300mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg of daily oral aspirin
Study: 28075064
Drug: Nebivolol-valsartan SPC
Normalized name: nebivolol / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol-valsartan SPC (5/80 mg/d)
Study: 28075064
Drug: Nebivolol or
Normalized name: nebivolol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol or valsartan monotherapy
Study: 28075064
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments (including SPCs, nebivolol, valsartan)
Study: 24296958
Drug: Dexmedetomidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.3 μg/kg)
Study: 17215657
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg/d
Study: 17215657
Drug: Olmesartan/HCTZ 40/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/HCTZ 40/12.5 mg/d
Study: 17215657
Drug: Olmesartan/HCTZ 40/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/HCTZ 40/25 mg/d
Study: 11488316
Drug: High initial
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High initial dose of budesonide (800 microg b.i.d)
Study: 11488316
Drug: Standard initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard initial dose of budesonide (200 microg b.i.d)
Study: 9590413
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg or 40 mg (duodenal and gastric ulcer protocols)
Study: 9590413
Drug: Rabeprazole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (all doses)
Study: 7921757
Drug: Efamol Marine
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efamol Marine (12 capsules daily for 9 months)
Study: 7921757
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 capsules daily for 9 months)
Study: 3246170
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular dose of ceftriaxone 50 mg/kg
Study: 3246170
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of amoxicillin 12.5 mg/kg t.i.d.
Study: 30101580
Drug: R.O.C.S. medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: R.O.C.S. medical minerals gel (group E3)
Study: 26653722
Drug: Topical NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical NSAID treatment on the day of surgery in the femtosecond laser group
Study: 26653722
Drug: Topical NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical NSAID treatment on the day of surgery in the conventional cataract surgery group
Study: 22548378
Drug: Positive Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Family Interaction Therapy (PFIT) - 12 weeks of individual child CBT plus 6 sessions of family treatment
Study: 22548378
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (ST) - 12 weeks of individual child CBT with weekly parent check‐ins and psychoeducation
Study: 21469215
Drug: Add-on mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add-on mirtazapine 30 mg during a 6-week double-blind phase
Study: 18798752
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (TAC) with onion extract gel
Study: 16391903
Drug: Lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification plus Metformin (LSM + MET)
Study: 10965417
Drug: Herbal combination
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal combination therapy comprising crataegus and camphor (Korodin Herz‐Kreislauf‐Tropfen)
Study: 10965417
Drug: Placebo identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical in colour and taste to the active treatment
Study: 1281728
Drug: Terazosin 10
Normalized name: terazosin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 10 mg
Study: 30443999
Drug: Ticagrelor 10
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 10 mg
Study: 20084109
Drug: Leucovorin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin (1 mg/kg daily for 12 months)
Study: 20084109
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mg/kg daily for 12 months)
Study: 20084109
Drug: Leucovorin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin with concomitant thyroxin treatment
Study: 20084109
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with concomitant thyroxin treatment
Study: 14740095
Drug: Gadodiamide administration
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide administration at 3 T
Study: 14740095
Drug: Cumulative triple-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative triple-dose 3 T images
Study: 14740095
Drug: Cumulative triple-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative triple-dose 1.5 T images
Study: 9581302
Drug: Ampicillin-sulbactam (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam (100 mg/kg per day for 5 days)
Study: 7800155
Drug: Moclobemide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (up to 300 mg per day)
Study: 3050906
Drug: Diflunisal 500
Normalized name: diflunisal 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 500 mg (single dose)
Study: 3050906
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg (2-dose regimen)
Study: 3050906
Drug: Acetaminophen 500
Normalized name: acetaminophen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg (2-dose regimen)